GlobalRPh Renal Dosing Masterv7.4
Renal Dosing Master: fast drug lookup
Source review / handoff

Efavirenz/emtricitabine/tenofovir disoproxil fumarate (Atripla), fixed-dose oral tablet

One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.

Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.

Share or print this source review

1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.

Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.

Clinical context remains essential

Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.

Check source scope before reading a dose

Atripla - labeled renal guidance

Product / population
Efavirenz/emtricitabine/tenofovir disoproxil fumarate (Atripla), fixed-dose oral tablet
Renal method
Creatinine clearance (CrCl), mL/min; use the product-specific calculation
Source revision
DailyMed SPL version 3, effective 2013-05-03; posted May 06, 2013
Retrieved
2026-11-07
Local review status
Selected renal passages reviewed; independent clinician adjudication pending.

Documented differences and cautions on this drug

All record notes are retained here, including notes about sources not selected in this review.

Atripla - product and source limitations

Check all three agents. The renal rules for tenofovir alafenamide products differ.

What to reconcile: Verify the current prescribing information for this presentation.

Selected renal passages reviewed; independent clinician adjudication pending.

Open this note and its source references
Official

Atripla - labeled renal guidance

Open original reference

DailyMed / product prescribing information · Efavirenz/emtricitabine/tenofovir disoproxil fumarate (Atripla), fixed-dose oral tablet

Renal method: Creatinine clearance (CrCl), mL/min; use the product-specific calculation
Source date: DailyMed SPL version 3, effective 2013-05-03; posted May 06, 2013
Retrieved: 2026-11-07

Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.

Selected renal passages reviewed; independent clinician adjudication pending.

Renal guidance: Renal impairment and fixed-dose limitations

Below CrCl 50 mL/min, the fixed combination is not recommended. Its components cannot be adjusted individually in this tablet. Check all three agents. The renal rules for tenofovir alafenamide products differ.

RDM73-atripla-official-1 · Source locator: Renal guidance: Renal impairment and fixed-dose limitations

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2096a07e-8601-4bdc-ba5a-338a40cd02e9
Retrieved
2026-11-07
Renal-function method
Creatinine clearance (CrCl), mL/min; use the product-specific calculation
Source date/version
DailyMed SPL version 3, effective 2013-05-03; posted May 06, 2013
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
840ca88d6bfbc10c7d8d582da7cf3cc5a1caaa55fb1e50f87aee4d779e7198a8

Document the clinical decision separately

This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.

GlobalRPh Renal Dosing Master v7.4. Review the retrieval and revision dates attached to each source. Selecting a reference does not imply clinical verification.

Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=efavirenz-emtricitabine-tdf-atripla&s1=RDM73-atripla-official&h1=fde4034099b9330fd21d7d3e34be7b086d0e709107a87b6e75c78f4c54b1e285

Top